Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6496 to 6510 of 8905 results

  1. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

  2. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

  3. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

  4. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

  5. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

  6. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

  7. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

  8. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

  9. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

  10. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

  11. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

  12. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

  13. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

  14. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

  15. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403